Delivery Order SPE2DB22D9239-SPE2DB24FDK66

Award Date 6/27/24
Potential Completion Date 7/19/24
Potential Value $15K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,358.74 contract is for the supply of Kadcyla 100 mg vials, with a period of performance through August 28, 2024. DMS Pharmaceutical Group holds a large single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued up to $499,999,999, which allows the...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $15,358.74, is for the supply of Kadcyla 100 mg vials, an oncology drug, with a period of performance through May 24, 2024. This order is issued under DMS Pharmaceutical Group's existing indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has a ceiling value of $15,358.74 and covers the delivery of Kadcyla 100 mg vials, a specialty oncology medication, with a completion date of August 15, 2024. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $15,358.74, is for the delivery of Kadcyla 100 mg vials, a specialty oncology drug, with a performance period that runs through August 22, 2024. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is valued at $13,327.42 and covers the delivery of Kadcyla 160 mg vials, a specialty oncology drug, with a period of performance through August 6, 2024. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $15,358.74 contract is for the supply of Kadcyla 100 mg vials, a prescription oncology drug, with a completion date of August 13, 2024. DMS Pharmaceutical Group holds a single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $24,623.52, is for the delivery of the oncology drug Kadcyla 160 mg vials to support the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $22,713.36 award is for the supply of Kadcyla 160 mg vials, with a period of performance through November 18, 2022. DMS Pharmaceutical Group holds a $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue firm fixed-price...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is valued at $51,195.60 and has a completion date of February 15, 2024. The contract is for the supply of Kadcyla 100 mg vials, a specialized oncology medication, to support the recurring medical supply needs of military health facilities worldwide. This order is part...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $7,679.34 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This contract is for the delivery of 4,565,134,451 vials of the cancer drug Kadcyla 100 mg by July 31, 2024. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, that allows the agency to issue...
  • SPE2DB22D9239
    Indefinite Delivery Contract
  • SPE2DB22D9239-SPE2DB24FDK66
    Delivery Order

This is a Firm Fixed Price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,358.74 contract is for the supply of Kadcyla 100 mg vials, an oncology drug, with a period of performance through July 19, 2024.

DMS Pharmaceutical Group holds a larger $499,999,999 indefinite delivery contract (IDC) with DLA under the SPE2DB program, which allows the agency to issue delivery orders for a wide range of pharmaceutical products to support the medical supply needs of military health facilities worldwide. This contract award, issued on June 27, 2024, is not designated as a set-aside. Through its federal contracts, DMS Pharmaceutical Group provides branded, generic, and specialty medications, biologics, and medical consumables to the Department of Defense and Department of Veterans Affairs.

Generated 9/26/24, 9:12 AM